Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

被引：14

作者：

Garg, Amit ^{[1
]}

Maes, Andrea ^{[1
]}

Corr, Christy ^{[1
]}

Jin, Bo ^{[1
]}

Wadhwa, Tarun ^{[1
]}

Handa, Nikhil ^{[1
]}

Van Dyck, Kristien ^{[1
]}

De Lepeleire, Inge ^{[1
]}

Shah, Jinesh ^{[2
]}

Wagner, John A. ^{[1
]}

Krishna, Rajesh ^{[1
]}

机构：

[1] Merck & Co Inc, Whitehouse Stn, NJ USA

[2] Veeda Clin Res, Ahmadabad, Gujarat, India

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 03期

关键词：

Cholesteryl ester transfer protein inhibition; CYP3A; diltiazem; CETP INHIBITOR; DRUG-INTERACTION; BLOOD-PRESSURE; 3A ACTIVITY; MIDAZOLAM;

D O I：

10.1177/0091270010368676

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：436 / 439

页数：4

共 16 条

[1] DOSE OF MIDAZOLAM SHOULD BE REDUCED DURING DILTIAZEM AND VERAPAMIL TREATMENTS [J].

BACKMAN, JT ;

OLKKOLA, KT ;

ARANKO, K ;

HIMBERG, JJ ;

NEUVONEN, PJ .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (03) :221-225

[2] The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective [J].

Bjornsson, TD ;

Callaghan, JT ;

Einolf, HJ ;

Fischer, V ;

Gan, L ;

Grimm, S ;

Kao, J ;

King, SP ;

Miwa, G ;

Ni, L ;

Kumar, G ;

McLeod, J ;

Obach, SR ;

Roberts, S ;

Roe, A ;

Shah, A ;

Snikeris, F ;

Sullivan, JT ;

Tweedie, D ;

Vega, JM ;

Walsh, J ;

Wrighton, SA .

JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05) :443-469

[3] Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients [J].

Bloomfield, Daniel ;

Carlson, Gary L. ;

Sapre, Aditi ;

Tribble, Diane ;

McKenney, James M. ;

Littlejohn, Thomas W., III ;

Sisk, Christine McCrary ;

Mitchel, Yale ;

Pasternak, Richard C. .

AMERICAN HEART JOURNAL, 2009, 157 (02) :352-U20

[4] Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib [J].

Cannon, Christopher P. ;

Dansky, Hayes M. ;

Davidson, Michael ;

Gotto, Antonio M., Jr. ;

Brinton, Eliot A. ;

Gould, A. Lawrence ;

Stepanavage, Michael ;

Liu, Sherry Xueyu ;

Shah, Sukrut ;

Rubino, Joseph ;

Gibbons, Patrice ;

Hermanowski-Vosatka, Anne ;

Binkowitz, Bruce ;

Mitchel, Yale ;

Barter, Philip .

AMERICAN HEART JOURNAL, 2009, 158 (04) :513-+

[5]

Food and Drug Administration US Department of Health and Human Services, 2006, GUID IND DRUG INT ST

[6] Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone [J].

Forrest, M. J. ;

Bloomfield, D. ;

Briscoe, R. J. ;

Brown, P. N. ;

Cumiskey, A-M ;

Ehrhart, J. ;

Hershey, J. C. ;

Keller, W. J. ;

Ma, X. ;

McPherson, H. E. ;

Messina, E. ;

Peterson, L. B. ;

Sharif-Rodriguez, W. ;

Siegl, P. K. S. ;

Sinclair, P. J. ;

Sparrow, C. P. ;

Stevenson, A. S. ;

Sun, S-Y ;

Tsai, C. ;

Vargas, H. ;

Walker, M., III ;

West, S. H. ;

White, V. ;

Woltmann, R. F. .

BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) :1465-1473

[7]

FRIEDMAN EJ, 2010, AM SOC CLIN PHARM TH

[8]

HUANG SM, 2004, APPL PHARMACOKINETIC

[9]

Jones DR, 1999, J PHARMACOL EXP THER, V290, P1116

[10] Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects [J].

Krishna, R. ;

Bergman, A. J. ;

Jin, B. ;

Fallon, M. ;

Cote, J. ;

Van Hoydonck, P. ;

Laethem, T. ;

Gendrano, I. N., III ;

Van Dyck, K. ;

Hilliard, D. ;

Laterza, O. ;

Snyder, K. ;

Chavez-Eng, C. ;

Lutz, R. ;

Chen, J. ;

Bloomfield, D. M. ;

De Smet, M. ;

Van Bortel, L. M. ;

Gutierrez, M. ;

Al-Huniti, N. ;

Dykstra, K. ;

Gottesdiener, K. M. ;

Wagner, J. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (06) :679-683

← 1 2 →